Sponsored by

Manufacturing Legend Backs Greenfield Robotics

Howard Dahl spent decades building the machines that feed America. His family invented the Bobcat skid steer. The air drills planting nearly every commodity crop globally? Those too. Now Dahl is manufacturing weed-cutting robots for Greenfield Robotics out of his Fargo factory, and he wrote his own check on top of it. 

Greenfield's current fleet is sold out, with over $1 million in total revenue and robots in the field since 2020. Chipotle’s venture arm and KingsCrowd Capital are also on board. The robots slice weeds with centimeter precision, replacing herbicides linked to environmental damage and rising health concerns among farmers. 

Greenfield is now in Test the Waters under Reg A+. Reserving shares today locks in a 5% bonus that can grow to 20% the week the round opens to the public.

Greenfield Robotics is Testing The Waters under tier 2 of Regulation A. No money or other consideration is being solicited, and if sent in response will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement filed by the company with the SEC has been qualified by the SEC. Any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of acceptance given after the date of qualification. An indication of interest involves no obligation or commitment of any kind. “Reserving” shares is simply an indication of interest. There is no binding commitment for investors that reserve shares in this manner to ultimately invest and purchase the shares reserved of the company, or to purchase any shares of the company whatsoever.

LONGEVITY LATESTISSUE 16 · 24 JUNE 2026

LONGEVITY LATEST

The Evidence-Based Edge on Living Longer and Better

Issue 16 · The Sunshine Supplement Meets Its Trials · 24 June 2026

WELCOME

👋 Welcome

25,871 people. Five years. 2,000 IU of vitamin D every single day. The largest trial ever run on one of the world's best-selling supplements reported back — and it hadn't cut their cancer, their heart attacks, or their broken bones. Then a second big trial said the same. Then a third.

So either vitamin D does nothing, or the trials were aimed at the wrong people. This week we make the case that it's the second one — and that the whole question collapses into one you can answer about yourself before you swallow another capsule: are you actually short of it, or just topping up a tank that's already full?

In this issue:

🔬 Top 3: What vitamin D is genuinely for, what the big trials ruled out, and the one surprise finding — graded

Spotlight: The one blood number worth knowing — and whether you should even test it

🚨 Hype Check: "Optimise your D to 60–80" — the megadose protocol that runs the wrong way

📖 Deep Dive: Why the trials keep "failing" — and why that's the most reassuring news in the field

🍄 Superfood: The one food that makes vitamin D in sunlight, just like your skin does

🌡 Biohacking Corner: Get your vitamin D right for under £3

THIS WEEK'S ANALYSIS

🔬 Top 3 Interventions Under the Microscope

Three claims, graded. They sound like one topic — "should I take vitamin D?" — but they're three different questions, and they get three different answers. The usual hierarchy applies: RCT beats cohort beats mechanism.

1. Correcting a genuine deficiency — Evidence Grade: A

The question: what is vitamin D actually for?

What it is. Vitamin D lets your gut absorb calcium and your bones mineralise properly. Run truly short of it and the failure is visible — rickets in children, osteomalacia (soft, aching bones) in adults. This is the job the vitamin was discovered doing, and on this job the evidence is about as settled as nutrition gets.

Human evidence. When someone is genuinely deficient — a UK blood level under 25 nmol/L — replacing it works, reliably and sometimes dramatically. Care-home residents, people who cover up or rarely get outside, those with malabsorption: correct the deficiency and bone pain eases, muscle function improves, fracture risk in the frailest falls. The catch is the word deficient: the benefit lives almost entirely in people who started low.

Cautions. Daily or weekly dosing, not giant monthly boluses (more on why that matters below). For most people a modest dose does the whole job.

Takeaway. This is the bedrock, and it's grade A — for the person who's actually short. Vitamin D isn't snake oil. It's a specific fix for a specific shortfall, and we've spent a decade selling it to everyone but the people it was meant for.

2. Preventing disease in people who are already replete — Evidence Grade: D

The question: does topping up an already-fine level buy you anything?

This is the claim the supplement aisle actually runs on — that a daily capsule is health insurance against cancer, heart disease and fractures for the general, well-fed adult. Three of the biggest trials ever run on a vitamin went looking for that payout and came back empty-handed.

VITAL (NEJM, 2019) randomised those 25,871 US adults to 2,000 IU a day and found no drop in cancer or cardiovascular disease; its 2022 follow-up on bones (NEJM) confirmed no reduction in total, hip or non-vertebral fractures either. DO-HEALTH (JAMA, 2020) gave 2,157 healthy Europeans over 70 the same dose and found nothing on falls, fractures, blood pressure or memory. D-Health (Lancet Diabetes & Endocrinology, 2022) dosed 21,315 older Australians for five years and didn't move mortality at all. These were big, rigorous trials — they simply asked whether topping up a general population prevents disease, and got a clean no. The reason is in their own write-ups: the participants were largely vitamin D replete to begin with.

Cautions. Here's the part that should end the "more is better" instinct for good. In STURDY (2020), doses of 2,000 and 4,000 IU a day produced more falls than 1,000 IU. Big monthly boluses are worse still — a 2016 trial found 60,000 IU a month raised blood levels but increased falls versus a lower dose. Past the point of sufficiency, pushing higher doesn't add benefit. Sometimes it subtracts.

Takeaway. As disease insurance for someone who isn't deficient, the policy doesn't pay out — and the evidence against it is strong, not merely absent. Evidence Grade D: a real nutrient, tested properly, in the wrong customer.

3. The autoimmune signal — Evidence Grade: B−

The question: is there one genuine surprise hiding in the null results?

There is, and I'll be honest that it's the entry I most wanted to inflate and won't. Buried in VITAL was a secondary finding that held up: people on vitamin D developed fewer new autoimmune diseases — rheumatoid arthritis, psoriasis, autoimmune thyroid disease and the like. The headline number was a 22% reduction (hazard ratio 0.78), reported in BMJ in 2022, and when the researchers kept following the group it was still there two years after the pills stopped.

That's biologically plausible — vitamin D is a real immune modulator — and it's a rare hard signal in a field full of nulls. So why only a B-minus? Because it's one trial, on a secondary endpoint, with a confidence interval that brushes right up against "no effect" (0.61–0.99). One strong result is a reason to run the next trial, not to rewrite the label.

Cautions. This is not a licence to megadose for prevention — the signal came from a standard 2,000 IU dose, not the 10,000 IU the internet will try to sell you off the back of this paragraph.

Takeaway. The most promising thing vitamin D has done in a decade, and still only B−, because science means waiting for the second trial. I'll be watching for it.

SPOTLIGHT

⭐ Spotlight Treatment: The One Blood Number — And Whether You Should Even Look

If there's a single number this issue wants you to know, it's your 25-hydroxyvitamin D — the storage form, the thing a "vitamin D test" actually measures. But knowing it and chasing it are very different acts, and the gap between them is where a lot of money changes hands.

In the UK the thresholds are refreshingly simple. Below 25 nmol/L is deficiency — the zone where replacing it genuinely changes your health. Between 25 and 50 is "insufficient." Above 50 nmol/L you're sufficient, full stop. That's the official line from the Scientific Advisory Committee on Nutrition, and it's the only number that reliably does anything when you act on it: are you below the deficiency line, or not?

Now watch the goalposts move online. American influencers quote the number in different units (ng/mL, which run 2.5 times smaller) and insist the "optimal" range is 50–80 — which in UK units is 125 to 200 nmol/L. That's up to four times the level your own health service calls sufficient, presented as the floor of normal. There is no trial showing that getting from 50 to 150 nmol/L prevents anything. The number got inflated by marketing, not by data.

Pros (when testing earns its place)

You have symptoms or a condition — bone pain, malabsorption, osteoporosis — where the result changes treatment.

You're in a high-risk group: housebound, darker skin with little sun, consistently covered up.

A one-off check to settle a genuine worry is cheap and reasonable.

Cons (when it's theatre)

The 2024 Endocrine Society guideline advised against routine testing in healthy people — because no target level for preventing disease has ever been established.

Repeat-testing to "optimise" toward an influencer number is chasing a target that doesn't exist.

A high reading tells you nothing useful; only a low one changes what you should do.

Bottom line: ⚠️ Worth one check, not a habit. A 25-OH-D test earns its place if you're symptomatic or in a risk group; it's theatre if you're repeat-testing to chase an "optimal" number no trial has ever validated. Find out whether you're below the deficiency line, then stop. Why a higher level isn't a better one is the Deep Dive's job.

HYPE CHECK

🚨 Hype Check: "Optimise Your D to 60–80"

The Hype. The protocol is everywhere on health TikTok and the podcast circuit: most people are "functionally deficient," the official targets are far too low, and you should take 5,000 to 10,000 IU a day — often bundled with K2 — to drive your level up to a "truly optimal" 60–80 ng/mL. High-strength D3 capsules cost almost nothing, which is exactly why they're easy to oversell.

The Evidence. Two problems, one fatal. First, there's no benefit to chase up there — no trial shows that a blood level of 150 nmol/L does anything a level of 60 doesn't. Second, the dose opens above the safety ceiling: US and EU bodies cap the tolerable upper intake at 4,000 IU a day, and the megadose protocol starts there and climbs. Outright poisoning takes far more — the alarming case reports usually involve 50,000 IU a day for months, blood calcium climbing and kidneys straining — but "probably won't poison me" is a low bar for a daily habit with no upside. And remember the falls data: higher daily doses and big monthly boluses made things worse, not better. The D-Health trial even saw a faint, unsettling uptick in cancer deaths in one exploratory analysis of its high-dose arm.

Why It's Misleading. It takes a true statement — deficiency is bad and worth fixing — and smuggles in a false one: that if some is good, more must be better. For a fat-soluble vitamin your body stores, that's precisely the wrong instinct.

Our Verdict: Not recommended as a megadose-to-a-number protocol. Keep vitamin D for correcting a real deficiency and topping up through a sunless winter. Stop using it for chasing an "optimal" blood reading, monthly mega-boluses, or the belief that more is more. The evidence-based dose is the dull one: 400–800 IU a day, for a couple of quid a year.

SUPERFOOD

🍄 Superfood Spotlight: UV-Exposed Mushrooms

Here's a genuinely lovely quirk of biology: mushrooms make vitamin D the same way your skin does. Their ergosterol turns to vitamin D2 under ultraviolet light — and since mushrooms are fungi, not plants, that makes them one of the very few non-animal foods that supply any vitamin D at all without fortification, which makes them genuinely useful if you're vegan.

The honest detail the packet won't mention: shop mushrooms are grown in the dark and contain almost none — under 1 microgram per 100g. The magic is the sunlight. Lay sliced button mushrooms gills-up on a windowsill in midday summer sun for fifteen minutes and they generate around 17 micrograms per 100g — comfortably more than the UK's 10-microgram daily target. Some supermarkets now sell UV-treated mushrooms that do this for you, labelled as such. One caveat for the purists: they make D2, and D2 raises your blood level a touch less efficiently than the D3 in oily fish or a capsule.

A punnet costs about £1. Slot it correctly: a real, repeatable food source of vitamin D — best as a winter top-up or the backbone of a vegan's strategy — not a replacement for the sunshine months or, if you're genuinely deficient, for proper treatment. Right job, right mushroom.

DEEP DIVE

📖 Deep Dive — Why the Vitamin D Trials Keep "Failing"

Here's the part the headlines got backwards. "Vitamin D doesn't work," they ran when the big trials came back null — but a flat result in people who weren't short of it isn't a failure. It's a clue. The Deep Dive follows that clue all the way down.

There's a U-shaped curve that explains why both too little and too much cost you, the reason the observational enthusiasts and the randomised sceptics are both telling the truth, and a decision map that drops you into exactly one of five rows — deficient, over-75, pregnant, prediabetic, or the already-fine majority who can put the bottle down. The whole point of the click is finding out which row is yours.

👉 Find out why "no effect" is the best news in the field: The Vitamin D Trials Didn't Fail. They Tested the Wrong People.

1,400 words · 7-minute read

BIOHACKING CORNER

🌡 Biohacking Corner: Get Your Vitamin D Right for Under £3

One nutrient, five rules, and almost no spending. I ran my own level once, found it unremarkable, and stopped thinking about it — which is roughly the goal here.

1. Let your skin do the work in summer. From about April to September in the UK, short, regular midday sun on bare forearms and face makes plenty — often 10 to 30 minutes, though darker skin needs longer for the same yield. No burning, no tanning beds, no heroics.

2. Take the dull winter dose. From October to March there isn't enough UK sunlight to make any, whatever your skin. Public Health England's line is the right one: 10 micrograms (400 IU) a day through the dark months. A year's supply is a couple of pounds.

3. Test only if you're in a risk group. Symptoms, malabsorption, osteoporosis, very little sun exposure, darker skin and covered up, over 75, or pregnant — those are reasons to check. "I saw a podcast about it" is not.

4. Eat the vitamin as well as swallowing it. Oily fish, egg yolks, UV mushrooms and fortified foods all contribute. Food makes the supplement a top-up, not a crutch.

5. Don't megadose, and never bolus. Daily beats giant monthly hits, and once you're sufficient, more buys nothing. Stay near the recommended dose — that's where the evidence sits, not the top of the lab range.

Personal note: I spent an embarrassing winter convinced I needed to "optimise," took 5,000 IU a day for months, retested, and learned the only thing it had optimised was the supplement company's revenue. Back to 400 IU and a tin of sardines.

Caveat: if you have sarcoidosis or another granulomatous condition, a history of kidney stones, high blood calcium, or take thiazide diuretics, vitamin D can push your calcium too high — get medical advice before supplementing, and don't self-prescribe high doses.

READER PULSE

📊 Reader Pulse

Last issue's electrolyte poll landed about where the argument pointed: the biggest bracket, roughly 41%, was "I make my own / just use food and water," with "daily out of habit" smaller than the powder brands would like you to believe. One reply stuck with me: "Read the issue, cancelled the subscription, kept the salt cellar. Net saving: £44 a month." That's the whole newsletter in one sentence.

This week's question sets up a possible follow-up. If "I take it but have no idea what my level is" turns out to be the biggest group, we'll run a plain-English guide to reading your own blood result without falling for the optimise-to-a-number trap.

What's your relationship with vitamin D?

I take it daily and know my blood level

I take it daily but have no idea what my level is

Only in autumn and winter

I rely on sun and food

Never thought about it

CLOSING

🎯 Closing

If this issue changes one habit, let it be subtraction, not addition. Most of us can stop chasing a number and let a £3 winter capsule and a walk in the spring sun do the whole job. The people who genuinely need more already have a reason — and after this issue, they know what it is.

Issue 17 keeps us on the supplement shelf and turns to the other nutrient half the internet swears you're deficient in: magnesium. Glycinate versus citrate versus the cheap oxide that barely absorbs, what the sleep and blood-pressure trials actually show, and whether "everyone's deficient" survives contact with the data.

Stay curious and stay healthy!

Christian Thomsen, Editor

Longevity Latest is published weekly by FrontWave Media Ltd. The content is for educational purposes and does not constitute medical advice. Vitamin D interacts with blood calcium, kidney function, and certain conditions and medications: if you have sarcoidosis or another granulomatous dis

© 2026 FrontWave Media Ltd · Longevity Latest1

Turn Your Opinions Into Profit

Join millions of traders putting their knowledge to work on real-world events—from inflation to elections. Buy “Yes” or “No” shares and earn if you’re right.

No house. Peer-to-peer. Cash out anytime.

Get a free $10 to start. Claim it and start trading now.

Trade responsibly.

Keep Reading